Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

A Short History of Rheumatoid Arthritis Therapeutics

Simon M. Helfgott, MD  |  Issue: January 2012  |  January 13, 2012

Simon M. Helfgott, MD

Why did you want to become a rheumatologist? For me, the decision wasn’t hard. As a medical resident, reading electrocardiograms at 2 am—or at 2 pm for that matter—didn’t appeal to me. Endocrinology seemed to lack any complexity; a simple look at lab tests either meant the patient was or was not hypothyroid. I lacked the passion for inserting endoscopes into any orifice. I had whittled my choices to a few remaining possibilities, and then I experienced a defining medical moment. I am referring to those clinical experiences that can immediately transform you and set you on your career path.

It happened during my junior residency year. I was in charge of a moderately busy medical ward consisting of older patients battling pneumonias or a flare of their chronic obstructive pulmonary disease brought on by exposure to the fierce winds and endless snowfalls of January in Montreal. It was there that I met Michael.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Dr. Koch isolating the Rinderpest virus in his laboratory.

Michael (name has been changed) was a delightful adolescent male, at least 40 years younger than any of my other patients. He had a long history of systemic juvenile arthritis. His illness began when he was five and it never let up. I was shocked to learn that he was nineteen years old; his growth had been stunted by his disease, leaving him no taller than about 4 feet 5 inches. His cherubic, slate grey face with undersized mandibles displayed the ravages of too many years of prednisone and gold therapies. He had already undergone several orthopedic procedures and one of them, his knee replacement, had become infected.

He was admitted for a lengthy stay consisting of surgery, followed by a prolonged course of antibiotics, followed by more surgery. Yet Michael’s resilience and determination to get better never wavered. He was upbeat and cheerful to a fault. Many years later, I learned that this personality trait was a common characteristic among rheumatoid arthritis (RA) patients, especially those with more severe disease. Yet what struck me most about Michael’s care was his treatment with gold, specifically intramuscular gold shots given every two weeks.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Origins of Gold Treatment

Like so many stories in medicine about the origins of particular therapies, this one gets a bit confusing. Many Europeans claim credit for the idea of using gold to treat RA. In fact, it seems that just about every country in the European Union lays claim to having been the “first” to discover the benefits of this mineral therapy. In a wonderful review of the topic published in 1945 by Dr. Thomas Fraser of Glasgow, the author traces the origins of gold therapy to 1890 when Dr. Heinrich Hermann Robert Koch (of Koch Postulates fame) first described the benefits of gold in inhibiting the in vitro growth of the tubercle bacillus.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Biologics/DMARDsConditionsDrug UpdatesOpinionProfilesResearch RheumRheumatoid ArthritisRheuminationsSpeak Out Rheum Tagged with:BiologicsdrugEducationHelfgottMethotrexateprednisoneProfileResearchresidencyRheumatoid arthritisrheumatologist

Related Articles
    Lost and found

    A Look Back at the First Use of Cortisone in Rheumatoid Arthritis

    January 17, 2023

    In 1949, the first description of patients with rheumatoid arthritis (RA) given cortisone sent shockwaves through the medical community, quickly capturing the public imagination as well. The paradigm-shifting report paved the way for the use of cortisone and related drugs in RA and many other medical conditions.1 The following is a discussion of some of…

    TNF Blockade for SLE

    September 1, 2010

    Reckless approach versus missed opportunity?

    RheumMadness 2023: The Results Are In

    September 11, 2023

    RheumMadness is an online tournament in which a bracket of teams, representing key learning concepts in rheumatology, compete against each other in a series of head-to-head matchups, much like basketball teams in the NCAA’s March Madness. The 2023 tournament theme was The All Star Season. Each team represented one all star article competing to be…

    Are We Playing It Safe?

    October 1, 2010

    Tumor necrosis factor alpha inhibition and the risk of solid malignancies

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences